Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer

被引：0
|
作者：
Powers, Marissa V.
Swap, Swee Y.
te Poele, Robert
Lampraki, Eirini-Maria
Roe, Toby
Pellegrino, Loredana
Taskinen, Maria
Eccles, Suzenne
Raynaud, Florence
Cheeseman, Matthew
Jones, Keith
Clarke, Paul A.
Workman, Paul
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-PR-002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR-002
引用
收藏
页数：2
相关论文
共 6 条
  • [1] From targeted phenotypic screen to NXP800: A clinical stage activator of the integrated stress response for the treatment of ARID1A-mutated ovarian carcinoma
    Workman, Paul
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800
    Powers, Marissa V.
    Sharp, Swee Y.
    Lampraki, Eirini-Maria
    Roe, Toby
    Pellegrino, Loredana
    Taskinen, Maria
    Poele, Robert Te
    Raynaud, Florence
    Eccles, Suzanne
    Cheeseman, Matthew
    Jones, Keith
    Clarke, Paul A.
    Workman, Paul
    CANCER RESEARCH, 2023, 83 (08)
  • [3] A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800101; GOG-3087)
    Banerjee, Susanaoh
    Eskander, Ramez
    Roxburgh, Patricia
    O'Malley, David
    Oaknin, Ana
    Barlin, Joyce
    Van Nieuwenhuysen, Els
    Anderson, Charles
    Baurain, Jean-Francois
    Brubaker, Lindsay
    Ang, Joo Ern
    Cloven, Noelle
    Redondo, Andres
    Monk, Bradley
    Ray-Coquard, Isabelle
    Moore, Kathleen
    Berton, Dominique
    Sardone, Megan
    Marsolini, Diane
    Westin, Shannon
    GYNECOLOGIC ONCOLOGY, 2024, 190
  • [4] A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800101; GOG-3087)
    Banerjee, Susana
    Eskander, Ramez
    Roxburgh, Patricia
    O'Malley, David
    Oaknin, Ana
    Barlin, Joyce
    Van Nieuwenhuysen, Els
    Anderson, Charles
    Baurain, Jean-Francois
    Brubaker, Lindsay
    Ang, Joo Ern
    Cloven, Noelle
    Redondo, Andres
    Monk, Bradley
    Ray-Coquard, Isabelle
    Moore, Kathleen
    Berton, Dominique
    Sardone, Megan
    Marsolini, Diane
    Westin, Shannon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S302 - S302
  • [5] Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800-A new developmental agent for platinum-resistant ARID1A mutant ovarian cancer
    Powers, Marissa V.
    Hodgson, Rachel
    Sharp, Swee Y.
    Roe, Toby
    Allen, K. Elizabeth
    Campbell, Susan
    te Poele, Robert
    Cheeseman, Matthew
    Jones, Keith
    Clarke, Paul A.
    Workman, Paul
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Discovery of ARID1A loss as a patient biomarker for NXP800-A developmental activator of the integrated stress response (ISR) and inhibitor of the HSF1 pathway in ovarian cancer
    te Poele, Robert H.
    Powers, Marissa
    Sharp, Swee
    de Billy, Emmanuel
    Taskinen, Maria
    Pellegrino, Loredana
    Gowan, Sharon
    Miah, Asadh
    Hayes, Angela
    Cheeseman, Matthew
    Jones, Keith
    Eccles, Suzanne
    Raynaud, Florence
    Clarke, Paul
    Workman, Paul
    CANCER RESEARCH, 2024, 84 (06)
1